secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2026-05-21T21:05:15+00:00
Accession:  0001193125-26-234848
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema announces Phase 1 data for OP-3136: tumor shrinkage in 13/19 evaluable, no DLTs
--------------------------------------------------------------------------------

- OP-3136 monotherapy well-tolerated up to 45 mg; no DLTs, no discontinuations due to TRAEs.
- Among 19 evaluable patients, 13 showed tumor shrinkage; 2 confirmed + 1 unconfirmed partial response.
- Most common TRAEs: dysgeusia (81% any grade), anemia (38%; 6% grade 3), neutropenia (34%; 28% grade 3).
- Dose-proportional PK; at ≥6 mg steady-state concentrations exceeded preclinical efficacy targets.
- Data presented at ASCO May 30; also presenting OPERA-02 Phase 3 trial-in-progress poster.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526234848/0001193125-26-234848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526234848/olma-20260521.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-234848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer